DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| ?V? | LOCK|!s | LOCK|lw&H^$ |
DSM-Firmenich Earnings: Solid Organic Sales Growth; Guidance Increased After One-Off Vitamins Boon
DSM-Firmenich reported solid third-quarter earnings and upgraded the 2024 adjusted EBITDA guidance by 5% to EUR 2.1 billion, citing a one-off tailwind in the vitamins market.
